

A tertiary care ambulatory heart failure pathway managing one-third of all admissions including older patients with similar quality to inpatient management

Authors: Amy Thomson-Anderson,^A Nicola Fawcett,^A Saniya Naseer,^A Anurup Kumar,^A Barbara Onen,^A Helen Nolte,^A Rebecca Bone,^A Jordan Bowen^A and James Gamble^A

Table 1. Patient characteristics and mortality for heart failure index admissions

Characteristics (n=1,919)	Inpatient (n=1,321)	Ambulatory (n=598)	Data missing	p ^a
Age, years, median (IQR)	82 (74–88)	81 (73–88)	0	0.218
Prior comorbidities				
Ischaemic heart disease, n (%)	441 (33)	199 (33)	0	0.964
Pulmonary disease, n (%)	284 (22)	117 (20)	3	0.627
Cerebrovascular disease, n (%)	205 (16)	63 (11)	8	0.014
Diabetes, n (%)	383 (29)	181 (30)	3	0.847
Hypertension, n (%)	691 (52)	337 (56)	3	0.255
Valvular heart disease, n (%)	225 (17)	96 (16)	4	0.835
Smoker, n (%)	108 (8)	52 (9)	395	0.093
Characteristics at admission				
Hypotension (bp <100 mmHg systolic), n (%)	128 (10)	30 (5)	0	0.001
NHYA breathlessness scale (1–4), median (IQR)	3 (3–4)	3 (3–3)	31	0.024
Heart rate on admission, beats per minute, median (IQR)	86 (71–102)	82 (69–97)	0	0.012
NtProBNP, pg/mL, median (IQR)	6,015 (2,398–14,340)	3,516 (1,773–8,717)	934 ^b	<0.001
Creatinine, µmol/L, median (IQR)	104 (70–149)	102 (78–140)	62	0.367
Haemoglobin, g/L, median (IQR)	119 (101–136)	124 (108–138)	1	0.002
Living alone, n (%)	523 (40)	196 (33)	103	0.016
Outcomes				
30-day mortality, n (%) ^c	570 (34)	28 (11)	0	<0.001
30-day mortality ^d (comorbidity corrected)				<0.001

^ap values calculated using ranksum tests for continuous variables and chi-squared test for categorical variables. ^bNtProBNP reading collected by heart failure nurses, awaiting confirmation from direct lab testing results. ^c30 day mortality - death in hospital or death within 30 days of discharge. ^dFrom multivariable regression models based on backwards elimination p<0.05, from mortality plus Table 1 factors. bp = blood pressure; IQR = interquartile range; NtProBNP = N-terminal-pro-brain natriuretic peptide.

Introduction

Heart failure (HF) is the commonest cause of adult hospital admissions in the over 65s, accounting for over 67,000

admissions in England and Wales per year.¹ The average hospital stay lasts 13 days and costs around £3,800.² The increased use of same day emergency care (SDEC) services provide opportunity for novel HF management pathways while still achieving quality and best practice tariff targets³ in this setting.

Author: ^AOxford University Hospitals, Oxford, UK

Methods

An ambulatory HF pathway was established in a 'medical' SDEC unit supported by a specialist HF team and a Hospital At Home service providing intravenous diuretic therapy, clinical assessment and point-of-care diagnostics. Data were collected on every index HF admission as part of the National Heart Failure Audit, and as a service evaluation.

Results

From August 2019 to January 2021, 598/1,919 (31%) HF admissions were managed on an ambulatory pathway. Factors associated with inpatient management were hypotension, higher New York Heart Association Classification (NYHA) class, faster heart rate, higher N-terminal-pro-brain natriuretic peptide (BNP), lower haemoglobin, and living alone. Age was not associated with inpatient management. Patients managed via the ambulatory pathway were more likely to be referred to heart failure nurses and cardiology follow-up on discharge. There was no difference in the proportion seen by the specialist team within 24 hours, or having an echocardiography. Independent and comorbidity-corrected 30-day mortality was lower for ambulatory patients. Savings of approximately 5,000 bed-days are estimated.

Discussion

A third of heart failure management can be achieved via an ambulatory pathway irrespective of age without a clear difference in outcomes when compared with inpatient care. A large saving in inpatient bed usage can be achieved, despite cost of outreach teams. Mortality differences demonstrated are confounded by patient selection. Further evaluation of ambulatory pathways is needed to understand which patients benefit from ambulatory management, and better develop these services. ■

References

- 1 National Institute for Health and Care Excellence. *Acute heart failure: diagnosis and management: Clinical guideline [CG187]*. NICE, 2021. www.nice.org.uk/guidance/cg187 [Accessed 10 February 2022].
- 2 British Heart Foundation. *An integrated approach to managing heart failure in the community*. BHF, 2015.
- 3 NHS England. *2021/22 national tariff payment system*. NHSE, 2021. www.england.nhs.uk/wp-content/uploads/2020/11/21-22-National-tariff-payment-system.pdf [Accessed 10 February 2022].